Vaxart receives BARDA approval to initiate dosing of Phase 2b COVID-19 trial

Vaxart (VXRT) announced that it has received approval from the Biomedical Advanced Research and Development Authority, BARDA, part of the Administration for Strategic Preparedness and Response, ASPR, in the U.S. Department of Health and Human Services, to initiate dosing in the 10,000-participant portion of its ongoing Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate. “We are pleased to receive BARDA approval to move forward with dosing in this large-scale study and expect to dose the first patient in this cohort in the second quarter of 2025,” said Steven Lo, Chief Executive Officer of Vaxart. “We are deeply grateful for the continued support of our government partners at HHS and BARDA, whose collaboration is critical to advancing our clinical development program.”